查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574767

糖尿病肾臟病市场：按糖尿病类型、药物类别、最终用户、给药途径- 全球预测 2025-2030

Diabetic nephropathy Market by Diabetes Type, Drug Class (Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers), End-Use, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年糖尿病肾臟病市场价值为27.9亿美元，预计到2024年将达到29.3亿美元，复合年增长率为6.13%，预计到2030年将达到42.3亿美元。

糖尿病肾臟病是糖尿病的严重併发症，其特征是肾臟损害导致末期肾病变。该市场包括诊断测试、治疗和疾病管理解决方案。由于全球糖尿病盛行率上升和人口老化，糖尿病肾病变的盛行率不断上升，因此需要解决糖尿病肾臟病。治疗具有广泛的应用，从药物干预到监测设备和个人化治疗计划的技术进步。最终用途包括医院、诊所、研究机构和居家医疗环境。影响市场的关键成长要素包括生物技术和个人化医疗的进步、医疗保健服务的改善以及政府支持糖尿病管理计划的倡议。此外，意识的提高和官民合作关係也有助于市场成长。潜在的治疗机会在于开发针对糖尿病肾臟病潜在病理学机制的新治疗方法，以及将人工智慧整合到早期诊断和个人化治疗中。

主要市场统计
基准年[2023] 27.9亿美元
预测年份 [2024] 29.3亿美元
预测年份 [2030] 42.3亿美元
复合年增长率（%） 6.13%

然而，市场成长面临限制和挑战，例如先进治疗的高成本、新兴国家的认知度低以及严格的监管核准延迟了产品市场进入。为了利用新的商机，公司应该投资于创新且具有成本效益的治疗解决方案的研发，并利用数位健康技术的创新来增强疾病管理和患者依从性。与医疗保健提供者合作开发综合护理模式可以进一步扩大市场范围。理想的创新领域包括基因治疗、使用生物标记进行早期检测以及奈米药物传输系统的开发。考虑到市场的性质，该市场竞争激烈，重点是持续研究和协作努力来解决未满足的需求。为了实现永续成长，企业必须专注于创造负担得起的、高影响力的解决方案，并培养与学术和研究机构的伙伴关係，以在不断变化的情况中保持领先地位。

市场动态：揭示快速发展的糖尿病肾臟病市场的关键市场洞察

供需的动态交互作用正在改变糖尿病肾臟病变市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 糖尿病和慢性肾臟病盛行率的增加推动了对糖尿病肾臟病变治疗的需求
    • 医疗技术和治疗方案的进步可改善糖尿病肾臟病变市场的患者预后
    • 增加医疗支出和政府努力支持糖尿病肾臟病新治疗方法的开发
    • 提高患者和医疗保健提供者对糖尿病肾臟病早期诊断和管理的认识
  • 市场限制因素
    • 糖尿病肾臟病变有效治疗方案的可用性有限且高成本
    • 糖尿病肾臟病变长期管理增加患者的医疗费用和经济负担
  • 市场机会
    • 整合人工智慧和机器学习以进行高级诊断和风险分层
    • 投资病患教育计画以提高自我管理和治疗依从性
    • 与科技公司建立策略伙伴关係关係，开发先进的诊断工具
  • 市场问题
    • 糖尿病肾臟病市场的创新：透过先进的治疗方法解决未满足的临床需求
    • 克服糖尿病肾臟病市场挑战的策略方法：病患教育与依从性议题

波特五力：驾驭糖尿病肾臟病市场的策略工具

波特的五力框架是了解糖尿病肾臟病市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解糖尿病肾臟病市场的外部影响

外部宏观环境因素在塑造糖尿病肾臟病市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解糖尿病肾臟病市场的竞争格局

糖尿病肾臟病市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵糖尿病肾臟病市场供应商的绩效评估

FPNV定位矩阵是评估糖尿病肾臟病市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製糖尿病肾臟病变市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对糖尿病肾臟病市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 糖尿病和慢性肾臟病盛行率的增加增加了对糖尿病肾臟病变治疗的需求。
      • 随着医疗技术和治疗方案的进步改善患者的治疗效果，糖尿病肾臟病变市场
      • 医疗成本上升和政府支持新治疗方法开发的努力
      • 患者和医疗保健专业人员对糖尿病肾臟病早期诊断和治疗的意识不断增强
    • 抑制因素
      • 糖尿病肾臟病的有效治疗选择有限且成本高昂
      • 长期管理增加病患的医疗费用和经济负担
    • 机会
      • 整合人工智慧和机器学习以进行高级诊断和风险分类
      • 投资病患教育计画以增强自我管理和治疗依从性
      • 与科技公司建立策略伙伴关係，开发先进的诊断工具
    • 任务
      • 糖尿病肾臟病市场的创新：透过先进治疗方法解决未满足的临床需求
      • 克服糖尿病肾臟病市场挑战的策略方法：病患教育与依从性议题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 糖尿病肾臟病市场：依糖尿病类型

  • 介绍
  • 1型糖尿病
  • 2型糖尿病

第七章 糖尿病肾臟病市场：依药物类别

  • 介绍
  • 血管收缩素II 受体拮抗剂 (ARB)
  • 血管收缩素转化酵素(ACE) 抑制剂
  • 钙离子通道阻断剂
  • 利尿剂

第八章糖尿病肾臟病市场：依最终用途分类

  • 介绍
  • 诊所
  • 透析中心
  • 居家医疗
  • 医院

第九章糖尿病肾臟病市场：依给药途径

  • 介绍
  • 静脉
  • 口服
  • 皮下的

第十章北美及南美糖尿病肾臟病市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太糖尿病肾臟病市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲糖尿病肾臟病市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Vertex Pharmaceuticals 以 49 亿美元收购 Alpine Immune Sciences，以加强肾臟疾病治疗产品组合併引领 IgAN 市场
    • Sun Pharma 和拜耳合作在印度销售Finerenone，改善糖尿病肾臟病患者的治疗机会和治疗结果
    • FDA核准Jardiance治疗成人慢性肾臟病，在关键 III 期试验中将进展风险降低 28%
  • 战略分析和建议
Product Code: MRR-81515600A188

The Diabetic nephropathy Market was valued at USD 2.79 billion in 2023, expected to reach USD 2.93 billion in 2024, and is projected to grow at a CAGR of 6.13%, to USD 4.23 billion by 2030.

Diabetic nephropathy, a severe complication of diabetes, is characterized by kidney damage leading to end-stage renal disease. Its market encompasses diagnostic tests, therapeutics, and disease management solutions. The necessity of addressing diabetic nephropathy arises from its increasing prevalence, driven by the global rise in diabetes rates and an aging population. Applications range from pharmaceutical interventions to technological advancements in monitoring devices and personalized treatment plans. The end-use scope includes hospitals, clinics, research institutions, and home healthcare settings. Key influencing growth factors in the market include advancements in biotechnology and personalized medicine, the increasing accessibility of healthcare services, and government initiatives supporting diabetes management programs. Additionally, rising awareness and public-private partnerships contribute to market growth. Potential opportunities lie in the development of novel therapies targeting the underlying pathophysiological mechanisms of diabetic nephropathy, as well as the integration of artificial intelligence in early diagnosis and treatment personalization.

KEY MARKET STATISTICS
Base Year [2023] USD 2.79 billion
Estimated Year [2024] USD 2.93 billion
Forecast Year [2030] USD 4.23 billion
CAGR (%) 6.13%

However, market growth faces limitations and challenges such as the high cost of advanced treatments, limited awareness in developing countries, and stringent regulatory approvals that delay product market entry. To capitalize on emerging opportunities, businesses should invest in R&D for innovative, cost-effective treatment solutions and leverage digital health technology innovations that enhance disease management and patient compliance. Collaboration with healthcare providers for comprehensive care models could further expand market reach. The best areas for innovation include gene therapy, the use of biomarkers for early detection, and the development of nano-based drug delivery systems. Insights into the market's nature reveal it as highly competitive, with ongoing research and a focus on collaborative efforts to address unmet needs. For sustainable growth, businesses should focus on creating affordable, high-impact solutions and fostering partnerships with academic and research institutions to stay ahead in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic nephropathy Market

The Diabetic nephropathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes and chronic kidney disease driving the demand for Diabetic nephropathy treatments
    • Advancements in medical technology and treatment options improving patient outcomes in the Diabetic nephropathy market
    • Rising healthcare expenditures and government initiatives supporting the development of new Diabetic nephropathy therapies
    • Growing awareness about early diagnosis and management of Diabetic nephropathy among patients and healthcare providers
  • Market Restraints
    • Limited availability and high cost of effective treatment options for diabetic nephropathy
    • Increasing healthcare costs and economic burden on patients for long-term diabetic nephropathy management
  • Market Opportunities
    • Integrating artificial intelligence and machine learning for advanced diagnosis and risk stratification
    • Investing in patient education programs to enhance self-management and treatment adherence
    • Establishing strategic partnerships with technology companies for developing advanced diagnostic tools
  • Market Challenges
    • Innovating in the diabetic nephropathy market: addressing unmet clinical needs through advanced therapeutics
    • Strategic approaches to overcoming challenges in the diabetic nephropathy market: patient education and adherence issues

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic nephropathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic nephropathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic nephropathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic nephropathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic nephropathy Market

A detailed market share analysis in the Diabetic nephropathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic nephropathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic nephropathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic nephropathy Market

A strategic analysis of the Diabetic nephropathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic nephropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen, AstraZeneca, Bayer, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Dexcom, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck & Co., Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda Pharmaceutical, and Teva Pharmaceutical.

Market Segmentation & Coverage

This research report categorizes the Diabetic nephropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diabetes Type, market is studied across Type 1 Diabetes and Type 2 Diabetes.
  • Based on Drug Class, market is studied across Angiotensin II Receptor Blockers (ARBs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Calcium Channel Blockers, and Diuretics.
  • Based on End-Use, market is studied across Clinic, Dialysis Centers, Home Care, and In Hospital.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes and chronic kidney disease driving the demand for Diabetic nephropathy treatments
      • 5.1.1.2. Advancements in medical technology and treatment options improving patient outcomes in the Diabetic nephropathy market
      • 5.1.1.3. Rising healthcare expenditures and government initiatives supporting the development of new Diabetic nephropathy therapies
      • 5.1.1.4. Growing awareness about early diagnosis and management of Diabetic nephropathy among patients and healthcare providers
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability and high cost of effective treatment options for diabetic nephropathy
      • 5.1.2.2. Increasing healthcare costs and economic burden on patients for long-term diabetic nephropathy management
    • 5.1.3. Opportunities
      • 5.1.3.1. Integrating artificial intelligence and machine learning for advanced diagnosis and risk stratification
      • 5.1.3.2. Investing in patient education programs to enhance self-management and treatment adherence
      • 5.1.3.3. Establishing strategic partnerships with technology companies for developing advanced diagnostic tools
    • 5.1.4. Challenges
      • 5.1.4.1. Innovating in the diabetic nephropathy market: addressing unmet clinical needs through advanced therapeutics
      • 5.1.4.2. Strategic approaches to overcoming challenges in the diabetic nephropathy market: patient education and adherence issues
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic nephropathy Market, by Diabetes Type

  • 6.1. Introduction
  • 6.2. Type 1 Diabetes
  • 6.3. Type 2 Diabetes

7. Diabetic nephropathy Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Angiotensin II Receptor Blockers (ARBs)
  • 7.3. Angiotensin-Converting Enzyme (ACE) Inhibitors
  • 7.4. Calcium Channel Blockers
  • 7.5. Diuretics

8. Diabetic nephropathy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Clinic
  • 8.3. Dialysis Centers
  • 8.4. Home Care
  • 8.5. In Hospital

9. Diabetic nephropathy Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Americas Diabetic nephropathy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Diabetic nephropathy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Diabetic nephropathy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Vertex Pharmaceuticals to acquire Alpine Immune Sciences for USD 4.9 billion, boosting kidney disease treatment portfolio and leading IgAN market.
    • 13.3.2. Sun Pharma and Bayer collaborate to distribute Finerenone in India, boosting access and patient outcomes for CKD in diabetes
    • 13.3.3. FDA approves Jardiance for chronic kidney disease in adults, lowing risk progression by 28% in major phase III trial
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bayer
  • 5. Biocon
  • 6. Boehringer Ingelheim
  • 7. Bristol-Myers Squibb
  • 8. Dexcom
  • 9. Eli Lilly
  • 10. GlaxoSmithKline
  • 11. Johnson & Johnson
  • 12. Medtronic
  • 13. Merck & Co.
  • 14. Novartis
  • 15. Novo Nordisk
  • 16. Pfizer
  • 17. Roche
  • 18. Sanofi
  • 19. Takeda Pharmaceutical
  • 20. Teva Pharmaceutical

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEPHROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEPHROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DIABETIC NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DIABETIC NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEPHROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC NEPHROPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY IN HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. DIABETIC NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. DIABETIC NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2023